{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-23-000083","form_type":"8-K/A","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2023-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.262867+00:00","generated_at":"2026-06-09T22:42:09.295601+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Allogene appoints Geoffrey Parker as CFO with $490K salary and equity grants","bullets":["Geoffrey Parker appointed EVP, CFO, Principal Financial and Accounting Officer effective Oct 16, 2023.","Replaces David Chang and Jack Chen as interim principal financial and accounting officers.","Prior roles: COO/CFO of Tricida, CFO of Anacor (acquired by Pfizer for $5.2B), MD at Goldman Sachs.","Compensation: $490K base salary, 45% target bonus, stock option for 950K shares, RSU for 400K shares.","Performance RSU of 390K shares vests upon $18.00 share price or first FDA product approval by 2026/2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-23-000083","json":"https://secwatch.observer/filing/0001737287-23-000083.json","markdown":"https://secwatch.observer/filing/0001737287-23-000083.md","text":"https://secwatch.observer/filing/0001737287-23-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000083/0001737287-23-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000083/allo-20231016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T22:42:09.295601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"136e14c74b","claim":"Geoffrey Parker was appointed as Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Allogene Therapeutics, Inc..","evidence_excerpt":"appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective October 16, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000083/0001737287-23-000083-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"aa06811e42","claim":"David M. Chang changed role as Interim Principal Financial Officer at Allogene Therapeutics, Inc..","evidence_excerpt":"replacing David M. Chang, M.D., Ph.D. and Jack Chen in their capacities as the Company’s interim principal financial officer and interim principal accounting officer, respectively.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000083/0001737287-23-000083-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"replaced"},{"label":"Role","value":"Interim Principal Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e43bf1ccf8","claim":"Jack Chen changed role as Interim Principal Accounting Officer at Allogene Therapeutics, Inc..","evidence_excerpt":"replacing David M. Chang, M.D., Ph.D. and Jack Chen in their capacities as the Company’s interim principal financial officer and interim principal accounting officer, respectively.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000083/0001737287-23-000083-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"replaced"},{"label":"Role","value":"Interim Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}